Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.8/5
Genscript Biotech (1548 HK)
Watchlist
Contact IR
81
Analysis
Health Care
•
Hong Kong
Genscript Biotech Corp is biotech service company. The Company provides life science services and products and pre-clinical drug development services.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
23 Jul 2025 00:55
What Happens to China Healthcare? - The Soaring Shares, the Turning Point, and the Top Picks
China biotech is the biggest valuation driver for the industry, but primary market still lacks confidence in long-term outlook. Valuation bubble...
Xinyao (Criss) Wang
Follow
248 Views
Share
bullish
•
Genscript Biotech
•
13 Nov 2024 05:10
StubWorld: Hanwha Corp; Genscript Biotech/Legend Biotech
Hanwha Corp appears attractive here. The pushback is that HC is thinly traded. And Genscript’s deconsolidation has minimal impact on financials...
David Blennerhassett
Follow
351 Views
Share
bullish
•
Ascentage Pharma Group Corp
•
16 Jul 2025 00:55
Ascentage Pharma (6855.HK) Placement - Thoughts on The Placing Price and the Outlook
The Placing price of HK$68.6 has priced in successful licensing deal of APG-2575. US$1.5-2.375bn is a more reasonable valuation. Biotech sector...
Xinyao (Criss) Wang
Follow
329 Views
Share
bullish
•
China Medical System
•
30 Jun 2025 00:55
Pre-IPO China Medical System (867 HK) - About the IPO in Singapore and Concerns on Valuation Outlook
Listing in SGX opens a new chapter and CMS is undergoing pipeline adjustments and strategic transformation. But as valuation logic changes, license...
Xinyao (Criss) Wang
Follow
343 Views
Share
bearish
•
Innovent Biologics Inc
•
29 Jun 2025 01:19
China Healthcare Weekly (Jun.29) - Biotech Valuation Bubble Is About to Burst, Innovent's Placement
The valuation bubble of innovative drug companies may burst soon, with some founders/shareholders already cashing out. Innovent's Placing Price of...
Xinyao (Criss) Wang
Follow
310 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.55.3
x